Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Zelira Therapeutics ( (AU:ZLD) ) has issued an update.
Zelira Therapeutics has received a $1,070,000 cash refund from the Australian Federal Government’s R&D Tax Incentive Scheme. This refund will support the company’s ongoing clinical and product development programs, as well as initiatives for pipeline products and essential business operations, thereby strengthening its position in the cannabis medicine industry.
The most recent analyst rating on (AU:ZLD) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.
More about Zelira Therapeutics
Zelira Therapeutics is a global leader in the development of clinically validated cannabis medicines. The company focuses on creating innovative cannabis-based therapies and products, targeting a wide range of medical conditions.
Average Trading Volume: 5,836
Technical Sentiment Signal: Sell
Current Market Cap: A$4.16M
See more insights into ZLD stock on TipRanks’ Stock Analysis page.